Webcast: How Will Oral Cladribine and FTY-720 Impact the Multiple Sclerosis Market?

Agenda:

• How receptive are surveyed neurologists and MCOs to oral cladribine and FTY-720? How will the efficacy and safety profiles of these drugs influence surveyed neurologists’ prescribing decisions and surveyed MCOs’ reimbursement decisions for the two agents?
• To which patient populations will oral cladribine and FTY-720 be prescribed and in what line of therapy will they be used? How will their patterns of use affect their commercial potential?
• What impact will the emergence of oral cladribine and FTY-720 have on currently-marketed MS drugs?
• Do surveyed MCOs expect to include oral cladribine and FTY-720 on their formularies and on what formulary tiers do they expect to place these agents?
• What restrictions will MCOs place on oral cladribine and FTY-720 and how will the extent of formulary coverage of each agent affect its commercial prospects?